US biopharmaceutical finance and the sustainability of the biotech business model
AbstractIn the decade before the 2008 economic crisis, the US biotechnology industry was booming. In a 2006 book, Science Business: The Promise, the Reality, and the Future of Biotech, Gary Pisano implies that, given the 10–20 year time-frame for developing biotech products and the lack of profitability of the industry as a whole, the US biotech boom should not have happened. Yet the biotech industry has received substantial funding from venture-capital firms as well as from established companies through R&D alliances. Why would money from venture capitalists and big pharma flow into an industry in which profits are so hard to come by? The purpose of this article is to work toward a solution of what might be called the “Pisano puzzle”, and in the process to provide a basis for analyzing the industrial and institutional conditions under which the growth of the US biopharmaceutical (BP) industry is sustainable. One part of the answer has been the willingness of stock-market investors to absorb the initial public offerings (IPOs) of a BP venture that has not yet generated a commercial product, and indeed may never do so. The other part of the answer is that the knowledge base that BP companies can tap to develop products comes much more from government investments and spending than from business finance. Indeed, we show that, through stock buybacks and dividends, established corporations in the BP industry have been distributing substantial sums of cash to shareholders that may be at the expense of R&D. We use the framework that we have developed for analyzing the sustainability of the US BP business model to pose a number of key areas for future research and policy, with an emphasis on the implications of the financialization of this business model for the generation of safe and affordable BP drugs as well as the need for a theory of innovative enterprise.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Bibliographic InfoArticle provided by Elsevier in its journal Research Policy.
Volume (Year): 40 (2011)
Issue (Month): 9 ()
Contact details of provider:
Web page: http://www.elsevier.com/locate/respol
US biopharmaceutical innovation; R&D finance; Corporate governance; Orphan drug; Stock repurchase; Shareholder value;
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Brian J. Hall & Jeffrey B. Liebman, 1998.
"Are CEOs Really Paid Like Bureaucrats?,"
The Quarterly Journal of Economics,
MIT Press, vol. 113(3), pages 653-691, August.
- William Lazonick, 2010. "Innovative Business Models and Varieties of Capitalism: Financialization of the U.S. Corporation," Business History Review, Harvard Business School, vol. 84(4), pages 675â702, December.
- Gur Huberman, 2001. "Contagious Speculation and a Cure for Cancer: A Nonevent that Made Stock Prices Soar," Journal of Finance, American Finance Association, vol. 56(1), pages 387-396, 02.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2005. "Setting the record straight on setting the record straight: Response to the Light and Warburton rejoinder," Journal of Health Economics, Elsevier, vol. 24(5), pages 1049-1053, September.
- Véronique Bastin & Georges Hübner, 2006.
"Concentrated Announcements on Clustered Data: An Event Study on Biotechnology Stocks,"
Financial Management Association, vol. 35(1), Spring.
- Véronique Bastin & Georges Hübner, 2006. "Concentrated Announcements on Clustered Data: An Event Study on Biotechnology Stocks," Financial Management, Financial Management Association International, vol. 35(1), pages 129-157, 03.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
- William Lazonick, 2010. "The Chandlerian corporation and the theory of innovative enterprise," Industrial and Corporate Change, Oxford University Press, vol. 19(2), pages 317-349, April.
- McMillan, G. Steven & Narin, Francis & Deeds, David L., 2000. "An analysis of the critical role of public science in innovation: the case of biotechnology," Research Policy, Elsevier, vol. 29(1), pages 1-8, January.
- Arora, Ashish & Gambardella, Alfonso, 1994. "The changing technology of technological change: general and abstract knowledge and the division of innovative labour," Research Policy, Elsevier, vol. 23(5), pages 523-532, September.
- Josh Lerner & Alexander Tsai, 2000.
"Do Equity Financing Cycles Matter? Evidence from Biotechnology Alliances,"
NBER Working Papers
7464, National Bureau of Economic Research, Inc.
- Lerner, Josh & Shane, Hilary & Tsai, Alexander, 2003. "Do equity financing cycles matter? evidence from biotechnology alliances," Journal of Financial Economics, Elsevier, vol. 67(3), pages 411-446, March.
- William Lazonick, 2009. "Sustainable Prosperity in the New Economy? Business Organization and High-Tech Employment in the United States," Books from Upjohn Press, W.E. Upjohn Institute for Employment Research, number spne.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2005. "Extraordinary claims require extraordinary evidence," Journal of Health Economics, Elsevier, vol. 24(5), pages 1034-1044, September.
- Cockburn Iain M. & Stern Scott, 2010. "Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy," Capitalism and Society, De Gruyter, vol. 5(1), pages 1-50, July.
- Light, Donald W. & Warburton, Rebecca N., 2005. "Setting the record straight in the reply by DiMasi, Hansen and Grabowski," Journal of Health Economics, Elsevier, vol. 24(5), pages 1045-1048, September.
- Light, Donald W. & Warburton, Rebecca N., 2005. "Extraordinary claims require extraordinary evidence," Journal of Health Economics, Elsevier, vol. 24(5), pages 1030-1033, September.
- Michael E. Solt, 1993. "SWORD Financing of Innovation in the Biotechnology Industry," Financial Management, Financial Management Association, vol. 22(2), Summer.
- Lazonick William, 2009. "The New Economy Business Model and the Crisis of U.S. Capitalism," Capitalism and Society, De Gruyter, vol. 4(2), pages 1-70, October.
- Kolympiris, Christos & Kalaitzandonakes, Nicholas & Miller, Douglas, 2014. "Public funds and local biotechnology firm creation," Research Policy, Elsevier, vol. 43(1), pages 121-137.
- Licht, Georg & Pfirrmann, Oliver & Strohmeyer, Robert & Heinrich, Stephan & Tonoyan, Vartuhi & Eckert, Thomas & Woywode, Michael & Crass, Dirk & Sellenthin, Mark O., 2012. "Ex-post-Evaluierung der Fördermaßnahmen BioChance und BioChancePlus im Rahmen der Systemevaluierung "KMU-innovativ": Begleit- und Wirkungsforschung zur Hightech-Strategie," ZEW Dokumentationen 12-05, ZEW - Zentrum für Europäische Wirtschaftsforschung / Center for European Economic Research.
- Olga Bruyaka & Hanko Zeitzmann & Isabelle Chalamon & Richard Wokutch & Pooja Thakur, 2013. "Strategic Corporate Social Responsibility and Orphan Drug Development: Insights from the US and the EU Biopharmaceutical Industry," Journal of Business Ethics, Springer, vol. 117(1), pages 45-65, September.
- Lehoux, P. & Daudelin, G. & Williams-Jones, B. & Denis, J.-L. & Longo, C., 2014. "How do business model and health technology design influence each other? Insights from a longitudinal case study of three academic spin-offs," Research Policy, Elsevier, vol. 43(6), pages 1025-1038.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Zhang, Lei).
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.